Business
Alnylam to Webcast Presentation at 44th Annual J.P. Morgan Healthcare Conference
CAMBRIDGE, Mass., January 05, 2026--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will present a company overview and participate in a Q&A session at the 44th Annual J.P. Morgan Healthcare Conference on Monday, January 12, 2026 at 9:00 am PT (12:00 pm ET) at The Westin St. Francis in San Francisco. During the presentation, the Company will unveil its new five-year strategy, which will guide the Company’s next phase of growth.
About this update from Jp Morgan Chase & Co.
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":1552,"height":440,"url":"https://media.zenfs.com/en/business-wire.com/3b986962bba2faeb9ab5e1d348fc8b19"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/oPXZf4qySfUiCHneJfhBMA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTI3MjtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/3b986962bba2faeb9ab5e1d348fc8b19","width":960,"height":272},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/G4A_8vyP.OZM5QvyLigjLw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTI0MDA7aD02ODA7Y2Y9d2VicA--/https://media.zenfs.com/en/business-wire.com/3b986962bba2faeb9ab5e1d348fc8b19","width":1200,"height":340}},"lazy":false},{"type":"text","content":"CAMBRIDGE, Mass., January 05, 2026--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will present a company overview and participate in a Q&A session at the 44th Annual J.P. Morgan Healthcare Conference on Monday, January 12, 2026 at 9:00 am PT (12:00 pm ET) at The Westin St. Francis in San Francisco. During the presentation, the Company will unveil its new five-year strategy, which will guide the Company’s next phase of growth. The Company also plans to share an update on unaudited fourth quarter and full year 2025 global net product revenues and provide an outlook for 2026 product sales.","length":685,"tagName":"p"},{"type":"text","content":"A live audio webcast of both the presentation and Q&A session will be available on the Investors section of the Company’s website, www.alnylam.com/events. A replay will be available on the Alnylam website within 48 hours after the event.","length":241,"tagName":"p"},{"type":"text","content":"About Alnylam PharmaceuticalsAlnylam (Nasdaq: ALNY) has led the translation of RNA interference (RNAi) into a whole new class of innovative medicines with the potential to transform the lives of people afflicted with rare and prevalent diseases with unmet need. Based on Nobel Prize-winning science, RNAi therapeutics represent a powerful, clinically validated approach yielding transformative medicines. Since its founding in 2002, Alnylam has led the RNAi Revolution and continues to deliver on a bold vision to turn scientific possibility into reality. Alnylam’s commercial RNAi therap...